Skip to main content

Table 2 Risk of invasive breast cancer according to the HER2 Ile655Val polymorphism

From: A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer

Polymorphism Cases Controls OR* 95% CI* OR 95% CI
  N % N %     
All subjects         
   Ile/Ile 637 58.2 551 56.5 1 (Reference) 1 (Reference)
   Ile/Val or Val/Val 457 41.8 425 43.5 0.92 0.76–1.10 0.90 0.75–1.09
Ile/Val 396 36.2 356 36.5 0.96 0.79–1.16 0.97 0.79–1.18
Val/Val 61 5.6 69 7.1 0.71 0.49–1.04 0.63 0.42–0.92
Localized disease         
   Ile/Ile 425 58.5 551 56.5 1 (Reference) 1 (Reference)
   Ile/Val or Val/Val 301 41.5 425 43.5 0.91 0.74–1.12 0.90 0.73–1.12
Ile/Val 257 35.4 356 36.5 0.94 0.76–1.16 0.95 0.76–1.19
Val/Val 44 6.1 69 7.1 0.78 0.52–1.18 0.69 0.45–1.06
Regional or distant metastasis         
   Ile/Ile 195 57.5 551 56.5 1 (Reference) 1 (Reference)
   Ile/Val or Val/Val 144 42.5 425 43.5 0.96 0.74–1.25 0.96 0.73–1.27
Ile/Val 128 37.8 356 36.5 1.03 0.79–1.36 1.08 0.81–1.44
Val/Val 16 4.7 69 7.1 0.60 0.34–1.09 0.49 0.26–0.90
  1. *Logistic regression models conditional on age; logistic regression models conditional on age and adjusted for family history of breast cancer, recent alcohol consumption, parity, menopausal status, age at menopause, hormone replacement therapy use, age at menarche, height at age 25 years, weight at age 18 years, and weight change since age 18 years; for cases at diagnosis. CI, confidence interval; OR, odds ratio.